NEXTPOINT
Live / Allowed — Notice of allowance issued (as of 11 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 10 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99075293
- Mark type
- Stylized text
- Filed
- 10 Mar 2025
- Published for opposition
- 16 Sept 2025
- Attorney of record
- Chang Hong
Goods and services
- Class 001 — Chemicals: Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer; Antibodies for medical purposes
- Class 042 — Scientific and technological services: Pharmaceutical products development; Pharmaceutical research and development; Research and development of medicines; Research and development in the pharmaceutical and biotechnology fields; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research in the field of immunotherapy and immuno-oncology; Research and development in the field of immunotherapy and immuno-oncology
Owner
- NextPoint Therapeutics, Inc., Cambridge, MA, US
- NextPoint Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Sept 2025 — PUBLISHED FOR OPPOSITION
- 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Aug 2025 — ASSIGNED TO EXAMINER
- 29 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Mar 2025 — APPLICATION FILING RECEIPT MAILED
- 10 Mar 2025 — NEW APPLICATION ENTERED